Immune checkpoint inhibitors are drugs that inhibit immune checkpoints. These drugs allow immune cells to respond more strongly to cancer by blocking them. This blocks the \u201coff\u201d signal, allowing T-cells to kill cancer cells.<\/p>\n\n\n\n
Checkpoint inhibitors can be used to treat a variety of cancers, including lung cancer (NSCLC and SCLC), melanoma, breast cancer (triple-negative, metastatic breast cancer), Hodgkin lymphoma, Urothelial carcinoma, Renal cell cancer (RCC), and others. Immune checkpoint inhibitors outperform other commonly used treatment therapies, such as chemotherapy, in terms of survival time and potency against cancer cells.<\/p>\n\n\n\n
Nonetheless, a few side effects are associated with the use of immune checkpoint inhibitors that affect people in various ways. Furthermore, despite being a highly effective therapy option, there is a risk of developing resistance to checkpoint inhibitors because some patients do not respond at all (primary resistance; refractory) or stop responding over time (acquired resistance; relapsed).<\/p>\n\n\n\n
There are few FDA-approved checkpoint inhibitors for lung cancer treatment, such as Non-Small Cell Lung Cancer (NSCLC). It is estimated that in 2021, approximately 235K<\/strong> new lung cancer cases were diagnosed in the United States, with 131K <\/strong>people dying from the disease.<\/p>\n\n\n\n According to the estimates based on DelveInsight analysis, the total 7MM incident cases of checkpoint-inhibitor-treated patients<\/a> in 2021 were around 158K, out of which the highest cases were seen in the United States. The EU5 countries accounted for approximately 64K cases in 2021, and Japan had about 29K cases in 2021. The total incident cases of checkpoint-inhibitor-treated patients in 7MM are calculated by adding the cases in individual countries.<\/strong><\/p><\/blockquote>\n\n\n\n